GTX Inc. (GTXI) Friday revealed a reduction in force reflecting the delay in the potential commercialization of toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy. The reduction in force, effective immediately, represents approximately 28% of the total workforce. The company also said that the employees remaining with the company would not receive an increase in base salaries for 2010 or any bonus compensation for 2009.
GTx expects to record a charge of approximately $1.1 million related to the workforce reduction in the fourth quarter of 2009.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.